Get the Stockscreener App
134.46
5.54%
7.06
Illumina Inc stock is traded at $134.46, with a volume of 4.00M.
It is up +5.54% in the last 24 hours and down -11.59% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$127.40
Open:
$127.965
24h Volume:
4.00M
Relative Volume:
1.99
Market Cap:
$20.56B
Revenue:
$4.29B
Net Income/Loss:
$703.00M
P/E Ratio:
30.12
EPS:
4.4635
Net Cash Flow:
$993.00M
1W Performance:
+14.27%
1M Performance:
-11.59%
6M Performance:
+35.08%
1Y Performance:
+51.13%
1-Day Range:
$127.00
$134.76
1-Week Range:
$115.88
$134.76
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
134.46 | 19.48B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
521.11 | 195.41B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
210.64 | 148.05B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
656.73 | 52.76B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
121.38 | 34.22B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.38 | 31.67B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected MultiomicsPR Newswire APAC - PR Newswire Asia
Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating - TipRanks
Florida lab uses genome sequencing to diagnose children with rare diseases - Stock Titan
Primecap Management Co. CA Sells 73,220 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. Unveils Revolutionary Genomic Advancements - Devdiscourse
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally - The Motley Fool
The next generation is shaping the future of rare diseases - Illumina
Evercore ISI reiterates Illumina stock rating on competitive positioning By Investing.com - Investing.com India
Canaccord reiterates Illumina stock Hold rating after Roche pricing By Investing.com - Investing.com Canada
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Present - PharmiWeb.com
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics - PR Newswire
Vestmark Advisory Solutions Inc. Sells 22,703 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Bought by North Star Asset Management Inc. - MarketBeat
Illumina Genome Push Raises Questions On Growth, Adoption And Valuation - simplywall.st
Illumina launches TruPath Genome, setting a new standard in genomic insight - Investing News Network
Illumina Launches TruPath Genome Workflow Solution - marketscreener.com
Illumina's TruPath Genome offers rapid whole genome testing for rare disease - Stock Titan
NovaSeq X Series innovation roadmap - Illumina
Next Generation Sequencing Market Competitive Landscape - GlobeNewswire
Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Illumina unveils NovaSeq X upgrades with 40% output increase - Investing.com Australia
Illumina, Inc. (ILMN) Stock Analysis: Exploring a 15.62% Potential Upside in the Genomics Sector - DirectorsTalk Interviews
Faster DNA decoding: Illumina’s NovaSeq X gets 40% more data, higher accuracy - Stock Titan
Illumina Beat Q4 Earnings and Closed a $350M Acquisition. Here’s What Investors Need to Know - TIKR.com
Why Illumina Inc. stock is a must watch in 20252025 Support & Resistance & Free Verified High Yield Trade Plans - mfd.ru
Illumina, Inc. $ILMN Shares Sold by Vanguard Group Inc. - MarketBeat
Jupiter Asset Management Ltd. Makes New $16.69 Million Investment in Illumina, Inc. $ILMN - MarketBeat
This once-hot cancer-detection company’s stock got cut in half after a failed trial - MarketWatch
Illumina SVP Leckman sells $275k in stock By Investing.com - Investing.com South Africa
Illumina SVP Leckman sells $275k in stock - Investing.com Australia
Is It Time To Reassess Illumina (ILMN) After Recent Share Price Volatility - Yahoo Finance
We Think That There Are Some Issues For Illumina (NASDAQ:ILMN) Beyond Its Promising Earnings - 富途牛牛
Insider Sell: Patricia Leckman Sells Shares of Illumina Inc (ILM - GuruFocus
Illumina Stock is Down 80% From Its All-Time Highs: Can It Recover in 2026? - TIKR.com
DNA Sequencing Market Is Booming So Rapidly by 2033 | Thermo Fisher Scientific, Inc., Illumina - openPR.com
Illumina Single Cell RNA Seq helps advance avian conservation - Illumina
Buyout Rumor: What is the Moat Score of Illumina IncMarket Performance Summary & Weekly Top Stock Performers List - baoquankhu1.vn
Illumina To Webcast Upcoming Investor Conference - marketscreener.com
Illumina, Inc. (ILMN) Stock Analysis: Evaluating a 16% Upside Potential Amidst Strong Growth Metrics - DirectorsTalk Interviews
Decoding early synaptic failure in Alzheimer’s disease through multiomic analysis - Illumina
Illumina’s AI-Driven Data Vision Is Expanding — Will Multiomics Integration Unlock a Transformational Edge? - Smartkarma
The future of global food security may depend on quality agrigenomics software - Illumina
Illumina Conservation Deal Highlights New Genomics Demand And Valuation Debate - Sahm
How Illumina Inc. stock performs during Fed tightening cyclesDip Buying & Stepwise Entry and Exit Trade Signals - mfd.ru
Illumina (NASDAQ:ILMN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
From sample to insight: Streamlining analysis with the Illumina 5-base solution - Illumina
Illumina completes acquisition of SomaLogic from Standard BioTools - BizWest
Illumina, Inc. $ILMN Stock Holdings Lowered by Rhumbline Advisers - MarketBeat
Krilogy Financial LLC Takes $1.34 Million Position in Illumina, Inc. $ILMN - MarketBeat
Illumina Crash 10% on Earnings: Why the Stock Could Rebound to $185 in 2026 - TIKR.com
Decoding Illumina Inc (ILMN): A Strategic SWOT Insight - GuruFocus
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):